<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156895</url>
  </required_header>
  <id_info>
    <org_study_id>A4061075</org_study_id>
    <nct_id>NCT02156895</nct_id>
  </id_info>
  <brief_title>Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea</brief_title>
  <official_title>Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to monitor the usage of INLYTA® in real practice within label,
      including the adverse events associated with INLYTA®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is observational, non-interventional multi-center study in which subjects will be
      administered as part of routine practice at Korean health care centers by accredited
      physicians.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2018</start_date>
  <completion_date type="Anticipated">August 21, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 21, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event incidence</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
    <description>The clinical nature, incidence, duration, and severity of adverse events; discontinuation due to adverse events; outcome and possible causality will be monitored in this study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
    <description>Tumor response based on RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
    <description>ORR(Objective Response Rate) : the proportion of patients who have a partial or complete response to therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) within limited follow-up period</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
    <description>Progression free survival (PFS) within limited follow up period due to limitation of study design (observation, non-interventional)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Progression (TTP)</measure>
    <time_frame>bimonthly up to 24 months</time_frame>
    <description>defined as the time to progression is one way to see how well a new treatment works</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced Renal Cell Carcinoma</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Korea who has a disease for which Axitinib is indicated
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients diagnosed as advanced renal cell carcinoma (aRCC) after failure of one prior
             systemic therapy.

          2. Patients to whom INLYTA® is first administered or patients who are already on INLYTA®
             during the study period

          3. Evidence of a personally signed and dated informed consent document indicating that
             the patient (or a legally acceptable representative) has been informed of all
             pertinent aspects of the study.

        Exclusion Criteria:

          1. Any patient who does not agree that Pfizer and companies working with Pfizer use
             his/her information

          2. Patients with hypersensitivity to axitinib or to any other component of INLYTA®

          3. Patients under 18

          4. Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Tower</name>
      <address>
        <city>Seoul</city>
        <zip>04631</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4061075&amp;StudyName=Post%20Marketing%20Surveillance%20Study%20to%20Observe%20Safety%20and%20Efficacy%20of%20Inlyta%20in%20South%20Korea</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4061075&amp;StudyName=Post+Marketing+Surveillance+Study+To+Observe+Safety+And+Efficacy+Of+Inlyta</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 6, 2014</study_first_submitted>
  <study_first_submitted_qc>June 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Korean PMS of Axitinib</keyword>
  <keyword>Metastatic RCC ; 2nd line only</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

